Viral proteases are another very important target for the development of antiviral therapies, as they are directly involved in the viral replication processes. Especially the Mpro is one of the best‐characterized viral targets, and numerous medicinal chemistry efforts have been already reported for the past outbreaks of SARS‐1 and MERS. Main proteases are highly conserved among other CoVs, which allows the development of broad spectral antiviral agents. Moreover, no human protease analog to the Mpro is known. Thus, drugs targeting Mpro could be highly virus‐selective and safe.